.jpg?format=webp&width=780)
A treat-to-target study will evaluate the efficacy and safety of ultra‐rapid lispro (URLi) versus lispro in a paediatric population with type 1 diabetes (T1D) in Phase 3. In children and adolescents with T1D, URLi demonstrated reasonable glycaemic control and noninferiority to lispro in HbA1c change for mealtime and postmeal URLi. In addition, when dosed at the beginning of meals, URLi reduced 1‐hour PPG and PPG excursions versus lispro.
Like
Save
Share